Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients

被引：11

作者：

Geng, Chuanying ^{[1
]}

Yang, Guangzhong ^{[1
]}

Wang, Huijuan ^{[1
]}

Wu, Yin ^{[1
]}

Leng, Yun ^{[1
]}

Zhou, Huixing ^{[1
]}

Zhang, Zhiyao ^{[1
]}

Jian, Yuan ^{[1
]}

Chen, Wenming ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Multiple myeloma; immunoparesis; survival; prognostic factors; UNINVOLVED IMMUNOGLOBULINS; CRITERIA;

D O I：

10.1080/10428194.2020.1855345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defined at least two suppressed uninvolved immunoglobulins. We found that patients with deep and partial immunoparesis had a significantly shorter median overall survival (OS) and progression-free survival (PFS). Moreover, deep and partial immunoparesis was a poor prognostic factor for OS and PFS in univariate and multivariable analyses. To reduce the bias between the groups, we performed a 1:1 propensity score matching technique for analysis and found that patients with deep and partial immunoparesis also had shorter OS and PFS. Our study showed that deep and partial immunoparesis can be defined an independent poor prognostic factor for patients with newly diagnosed MM.

引用

页码：883 / 890

页数：8

共 16 条

[1] Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma [J].

Chakraborty, Rajshekhar ;

Rybicki, Lisa ;

Nakashima, Megan O. ;

Dean, Robert M. ;

Faiman, Beth M. ;

Samaras, Christy J. ;

Rosko, Nathaniel ;

Dysert, Hayley ;

Valent, Jason ;

Anwer, Faiz .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) :1074-1082

[2] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[3] Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation [J].

Gao, Wen ;

Li, Jie ;

Wu, Yin ;

Li, Yanchen ;

Leng, Yun ;

Liu, Aijun ;

Yang, Guangzhong ;

Tian, Ying ;

Wang, Huijuan ;

Wang, Guorong ;

Wu, Zhipeng ;

Ren, Zhangyong ;

Chen, Wenming .

ANNALS OF HEMATOLOGY, 2019, 98 (05) :1177-1184

[4] Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation [J].

Gao, Wen ;

Li, Jie ;

Jian, Yuan ;

Yang, Guangzong ;

Wu, Yin ;

Li, Yanchen ;

Len, Yun ;

Liu, Aijun ;

Tian, Ying ;

Wang, Huijuan ;

Zhou, Huixing ;

Zhang, Zhiyao ;

Chen, Wenming .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) :169-174

[5] Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma [J].

Gonzalez-Calle, Veronica ;

Cerda, Seila ;

Labrador, Jorge ;

Sobejano, Eduardo ;

Gonzalez-Mena, Beatriz ;

Aguilera, Carmen ;

Maria Ocio, Enrique ;

Belen Vidriales, Maria ;

Puig, Noemi ;

Carmen Gutierrez, Norma ;

Garcia-Sanz, Ramon ;

Maria Alonso, Jose ;

Lopez, Rosa ;

Aguilar, Carlos ;

Garcia de Coca, Alfonso ;

Hernandez, Roberto ;

Mariano Hernandez, Jose ;

Escalante, Fernando ;

Mateos, Maria-Victoria .

HAEMATOLOGICA, 2017, 102 (05) :922-931

[6] Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials [J].

Heaney, Jennifer L. J. ;

Campbell, John P. ;

Iqbal, Gulnaz ;

Cairns, David ;

Richter, Alex ;

Child, J. Anthony ;

Gregory, Walter ;

Jackson, Graham ;

Kaiser, Martin ;

Owen, Roger ;

Davies, Faith ;

Morgan, Gareth ;

Dunn, Janet ;

Drayson, Mark T. .

LEUKEMIA, 2018, 32 (08) :1727-1738

[7] Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution [J].

Jimenez-Zepeda, Victor H. ;

Duggan, Peter ;

Neri, Paola ;

Chaudhry, Ahsan ;

Tay, Jason ;

Bahlis, Nizar .

LEUKEMIA & LYMPHOMA, 2018, 59 (08) :1920-1926

[8] Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma [J].

Kastritis, E. ;

Zagouri, F. ;

Symeonidis, A. ;

Roussou, M. ;

Sioni, A. ;

Pouli, A. ;

Delimpasi, S. ;

Katodritou, E. ;

Michalis, E. ;

Michael, M. ;

Hatzimichael, E. ;

Vassou, A. ;

Repousis, P. ;

Christophoridou, A. ;

Kartasis, Z. ;

Stefanoudaki, E. ;

Megalakaki, C. ;

Giannouli, S. ;

Kyrtsonis, M-C ;

Konstantopoulos, K. ;

Spyroupoulou-Vlachou, M. ;

Terpos, E. ;

Dimopoulos, M. A. .

LEUKEMIA, 2014, 28 (10) :2075-2079

[9] Review of 1027 patients with newly diagnosed multiple myeloma [J].

Kyle, RA ;

Gertz, MA ;

Witzig, TE ;

Lust, JA ;

Lacy, MQ ;

Dispenzieri, A ;

Fonseca, R ;

Rajkumar, SV ;

Offord, JR ;

Larson, DR ;

Plevak, ME ;

Therneau, TM ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :21-33

[10] Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma [J].

Ludwig, Heinz ;

Milosavljevic, Dejan ;

Berlanga, Oscar ;

Zojer, Niklas ;

Huebl, Wolfgang ;

Fritz, Veronique ;

Harding, Stephen .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) :295-301

← 1 2 →